Isoniazid mediates the CYP2B6*6 genotype-dependent interaction between efavirenz and antituberculosis drug therapy through mechanism-based inactivation of CYP2A6

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 7, 2014, Pages 4145-4152

  Court, Michael H ^a   Almutairi, Fawziah E ^b,c   Greenblatt, David J ^b   Hazarika, Suwagmani ^b   Sheng, Hongyan ^a   Klein, Kathrin ^d,e   Zanger, Ulrich M ^d,e   Bourgea, Joanne ^f   Patten, Christopher J ^f   Kwara, Awewura ^g  

^a WASHINGTON STATE UNIVERSITY   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c TUFTS UNIVERSITY   (United States)

^d DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

^e UNIVERSITY OF TÜBINGEN   (Germany)

^f BD Biosciences   (United States)

^g BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2A6; CYTOCHROME P450 2B6; EFAVIRENZ; ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; TUBERCULOSTATIC AGENT; BENZOXAZINE DERIVATIVE; CYP2A6 PROTEIN, HUMAN; CYP2B6 PROTEIN, HUMAN;

ARTICLE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; ENZYME INHIBITION; GENOTYPE; HUMAN; HUMAN CELL; HYDROXYLATION; IN VITRO STUDY; INHIBITION KINETICS; LIVER MICROSOME; METABOLITE; PRIORITY JOURNAL; BLOOD; DRUG EFFECTS; DRUG INTERACTION; ENZYME ACTIVATION; GENETICS; METABOLISM;

ANTITUBERCULAR AGENTS; BENZOXAZINES; CYTOCHROME P-450 CYP2A6; CYTOCHROME P-450 CYP2B6; DRUG INTERACTIONS; ENZYME ACTIVATION; ETHAMBUTOL; HUMANS; HYDROXYLATION; ISONIAZID; MICROSOMES, LIVER; PYRAZINAMIDE; RIFAMPIN;

EID: 84903134862     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02532-14     Document Type: Article

References (40)

1. CDC. 2013. Recommendations for regimens for the concomitant treatment of tuberculosis and HIV infection in adults. CDC, Atlanta, GA. http://www.cdc.gov/ tb/TB-HIV-Drugs/default.htm.
2. Lawn SD, Meintjes G, McIlleron H, Harries AD, Wood R. 2013. Management of HIV-associated tuberculosis in resource-limited settings: a state-of-the-art review. BMC Med. 11:253. http://dx.doi.org/10.1186/1741-7015-11-253.
3. Marzolini C, Telenti A, Decosterd LA, Greub G, Biollaz J, Buclin T. 2001. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS 15:71-75. http://dx.doi.org/10.1097/00002030-200101050-00011. (Pubitemid 32055781)
4. Stahle L, Moberg L, Svensson JO, Sonnerborg A. 2004. Efavirenz plasma concentrations in HIV-infected patients: inter- and intraindividual variability and clinical effects. Ther. Drug Monit. 26:267-270. http://dx.doi.org/10.1097/ 00007691-200406000-00008. (Pubitemid 38703012)
5. Kwara A, Lartey M, Sagoe KW, Xexemeku F, Kenu E, Oliver-Commey J, Boima V, Sagoe A, Boamah I, Greenblatt DJ, Court MH. 2008. Pharmacokinetics of efavirenz when coadministered with rifampin in TB/HIV coinfected patients: pharmacogenetic effect of CYP2B6 variation. J. Clin. Pharmacol. 48:1032-1040. http://dx.doi.org/10.1177/0091270008321790.
6. Kwara A, Lartey M, Sagoe KW, Court MH. 2011. Paradoxically elevated efavirenz concentrations in HIV/tuberculosis-coinfected patients with CYP2B6 516TT genotype on rifampin-containing antituberculous therapy. AIDS 25:388-390. http://dx.doi.org/10.1097/QAD.0b013e3283427e05.
7. Friedland G, Khoo S, Jack C, Lalloo U. 2006. Administration of efavirenz (600 mg/day) with rifampicin results in highly variable levels but excellent clinical outcomes in patients treated for tuberculosis and HIV. J. Antimicrob. Chemother. 58:1299-1302. http://dx.doi.org/10.1093/jac/dkl399. (Pubitemid 44884158)
8. Matteelli A, Regazzi M, Villani P, De Iaco G, Cusato M, Carvalho AC, Caligaris S, Tomasoni L, Manfrin M, Capone S, Carosi G. 2007. Multiple-dose pharmacokinetics of efavirenz with and without the use of rifampicin in HIV-positive patients. Curr. HIV Res. 5:349-353. http://dx.doi.org/10.2174/ 157016207780636588. (Pubitemid 46785071)
9. Baciewicz AM, Chrisman CR, Finch CK, Self TH. 2013. Update on rifampin, rifabutin, and rifapentine drug interactions. Curr. Med. Res. Opin. 29:1-12. http://dx.doi.org/10.1185/03007995.2012.747952.
10. Wen X, Wang JS, Neuvonen PJ, Backman JT. 2002. Isoniazid is a mechanism-based inhibitor of cytochrome P450 1A2, 2A6, 2C19 and 3A4 isoforms in human liver microsomes. Eur. J. Clin. Pharmacol. 57:799-804. http://dx.doi.org/10.1007/s00228-001-0396-3. (Pubitemid 34143338)
11. Polasek TM, Elliot DJ, Somogyi AA, Gillam EM, Lewis BC, Miners JO. 2006. An evaluation of potential mechanism-based inactivation of human drug metabolizing cytochromes P450 by monoamine oxidase inhibitors, including isoniazid. Br. J. Clin. Pharmacol. 61:570-584. http://dx.doi.org/10.1111/j.1365- 2125.2006.02627.x.
12. Ward BA, Gorski JC, Jones DR, Hall SD, Flockhart DA, Desta Z. 2003. The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J. Pharmacol. Exp. Ther. 306:287-300. http://dx.doi.org/10.1124/jpet.103.049601. (Pubitemid 36734384)
13. Ogburn ET, Jones DR, Masters AR, Xu C, Guo Y, Desta Z. 2010. Efavirenz primary and secondary metabolism in vitro and in vivo: identification of novel metabolic pathways and cytochrome P450 2A6 as the principal catalyst of efavirenz 7-hydroxylation. Drug Metab. Dispos. 38:1218-1229. http://dx.doi.org/10.1124/dmd.109.031393.
14. Belanger AS, Caron P, Harvey M, Zimmerman PA, Mehlotra RK, Guillemette C. 2009. Glucuronidation of the antiretroviral drug efavirenz by UGT2B7 and an in vitro investigation of drug-drug interaction with zidovudine. Drug Metab. Dispos. 37:1793-1796. http://dx.doi.org/10.1124/dmd.109.027706.
15. Kwara A, Lartey M, Sagoe KW, Kenu E, Court MH. 2009. CYP2B6, CYP2A6 and UGT2B7 genetic polymorphisms are predictors of efavirenz mid-dose concentration in HIV-infected patients. AIDS 23:2101-2106. http://dx.doi.org/10.1097/QAD. 0b013e3283319908.
16. Kwara A, Lartey M, Sagoe KW, Rzek NL, Court MH. 2009. CYP2B6 (c. 516G->T) and CYP2A6 (*9B and/or*17) polymorphisms are independent predictors of efavirenz plasma concentrations in HIV-infected patients. Br. J. Clin. Pharmacol. 67:427-436. http://dx.doi.org/10.1111/j.1365-2125.2009.03368.x.
17. Zanger UM, Klein K. 2013. Pharmacogenetics of cytochrome P450 2B6 (CYP2B6): advances on polymorphisms, mechanisms, and clinical relevance. Front. Genet. 4:24. http://dx.doi.org/10.3389/fgene.2013.00024.
18. Jinno H, Tanaka-Kagawa T, Ohno A, Makino Y, Matsushima E, Hanioka N, Ando M. 2003. Functional characterization of cytochrome P450 2B6 allelic variants. Drug Metab. Dispos. 31:398-403. http://dx.doi.org/10.1124/dmd.31.4.398. (Pubitemid 36378517)
19. Zhang H, Sridar C, Kenaan C, Amunugama H, Ballou DP, Hollenberg PF. 2011. Polymorphic variants of cytochrome P450 2B6 (CYP2B6.4-CYP2B6.9) exhibit altered rates of metabolism for bupropion and efavirenz: a charge-reversal mutation in the K139E variant (CYP2B6.8) impairs formation of a functional cytochrome p450-reductase complex. J. Pharmacol. Exp. Ther. 338:803-809. http://dx.doi.org/10.1124/jpet.111.183111.
20. Hofmann MH, Blievernicht JK, Klein K, Saussele T, Schaeffeler E, Schwab M, Zanger UM. 2008. Aberrant splicing caused by single nucleotide polymorphism c.516G>T [Q172H], a marker of CYP2B6*6, is responsible for decreased expression and activity of CYP2B6 in liver. J. Pharmacol. Exp. Ther. 325:284-292. http://dx.doi.org/10.1124/jpet.107.133306. (Pubitemid 351439175)
21. McIlleron HM, Schomaker M, Ren Y, Sinxadi P, Nuttall JJ, Gous H, Moultrie H, Eley B, Merry C, Smith P, Haas DW, Maartens G. 2013. Effects of rifampin-based antituberculosis therapy on plasma efavirenz concentrations in children vary by CYP2B6 genotype. AIDS 27:1933-1940. http://dx.doi.org/10.1097/ QAD.0b013e328360dbb4.
22. Bertrand J, Verstuyft C, Chou M, Borand L, Chea P, Nay KH, Blanc FX, Mentre F, Taburet AM, CAMELIA Study Group. 2013. Dependence of efavirenz- and rifampicin-isoniazid-based antituberculosis treatment drug-drug interaction on CYP2B6 and NAT2 genetic polymorphisms: ANRS12154 study in Cambodia. J. Infect. Dis. 209:399-408. http://dx.doi.org/10.1093/infdis/jit466.
23. di Iulio J, Fayet A, Arab-Alameddine M, Rotger M, Lubomirov R, Cavassini M, Furrer H, Gunthard HF, Colombo S, Csajka C, Eap CB, Decosterd LA, Telenti A, Swiss HIV Cohort Study. 2009. In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function. Pharmacogenet. Genomics 19:300-309. http://dx.doi.org/10.1097/FPC.0b013e328328d577.
24. Court MH. 2010. Interindividual variability in hepatic drug glucuronidation: studies into the role of age, sex, enzyme inducers, and genetic polymorphism using the human liver bank as a model system. Drug Metab. Rev. 42:209-224. http://dx.doi.org/10.3109/03602530903209288.
25. Greenblatt DJ, Zhao Y, Venkatakrishnan K, Duan SX, Harmatz JS, Parent SJ, Court MH, von Moltke LL. 2011. Mechanism of cytochrome P450-3A inhibition by ketoconazole. J. Pharm. Pharmacol. 63:214-221. http://dx.doi.org/10.1111/j.2042- 7158.2010.01202.x.
26. Bertelsen KM, Venkatakrishnan K, Von Moltke LL, Obach RS, Greenblatt DJ. 2003. Apparent mechanism-based inhibition of human CYP2D6 in vitro by paroxetine: comparison with fluoxetine and quinidine. Drug Metab. Dispos. 31:289. http://dx.doi.org/10.1124/dmd.31.3.289.
27. Agrawal S, Singh I, Kaur KJ, Bhade SR, Kaul CL, Panchagnula R. 2002. Bioequivalence assessment of rifampicin, isoniazid and pyrazinamide in a fixed dose combination of rifampicin, isoniazid, pyrazinamide and ethambutol vs. separate formulations. Int. J. Clin. Pharmacol. Ther. 40:474-481. http://dx.doi.org/10.5414/CPP40474.
28. Panchagnula R, Sancheti P, Rungta S, Agrawal S, Kaul CL. 2003. Evaluation of bioequivalence of isoniazid and pyrazinamide in three and four drugs fixed dose combinations using WHO simplified protocol. Pharmacol. Res. 48:383-387. http://dx.doi.org/10.1016/S1043-6618(03)00175-0. (Pubitemid 36945337)
29. McIlleron H, Wash P, Burger A, Norman J, Folb PI, Smith P. 2006. Determinants of rifampin, isoniazid, pyrazinamide, and ethambutol pharmacokinetics in a cohort of tuberculosis patients. Antimicrob. Agents Chemother. 50:1170-1177. http://dx.doi.org/10.1128/AAC.50.4.1170-1177.2006.
30. Pargal A, Rani S. 2001. Non-linear pharmacokinetics of rifampicin in healthy Asian Indian volunteers. Int. J. Tuberc. Lung Dis. 5:70-79. (Pubitemid 32401879)
31. Chang KC, Leung CC, Yew WW, Kam KM, Yip CW, Ma CH, Tam CM, Leung EC, Law WS, Leung WM. 2008. Peak plasma rifampicin level in tuberculosis patients with slow culture conversion. Eur. J. Clin. Microbiol. Infect. Dis. 27:467-472. http://dx.doi.org/10.1007/s10096-007-0454-6. (Pubitemid 351713064)
32. Orr ST, Ripp SL, Ballard TE, Henderson JL, Scott DO, Obach RS, Sun H, Kalgutkar AS. 2012. Mechanism-based inactivation (MBI) of cytochrome P450 enzymes: structure-activity relationships and discovery strategies to mitigate drug-drug interaction risks. J. Med. Chem. 55:4896-4933. http://dx.doi.org/10. 1021/jm300065h.
33. Shebley M, Hollenberg PF. 2007. Mutation of a single residue (K262R) in P450 2B6 leads to loss of mechanism-based inactivation by phencyclidine. Drug Metab. Dispos. 35:1365-1371. http://dx.doi.org/10.1124/dmd.107.014985. (Pubitemid 47121777)
34. Bumpus NN, Sridar C, Kent UM, Hollenberg PF. 2005. The naturally occurring cytochrome P450 (P450) 2B6 K262R mutant of P450 2B6 exhibits alterations in substrate metabolism and inactivation. Drug Metab. Dispos. 33:795-802. http://dx.doi.org/10.1124/dmd.105.003749. (Pubitemid 40686633)
35. Talakad JC, Kumar S, Halpert JR. 2009. Decreased susceptibility of the cytochrome P450 2B6 variant K262R to inhibition by several clinically important drugs. Drug Metab. Dispos. 37:644-650. http://dx.doi.org/10.1124/dmd.108.023655.
36. Xu C, Ogburn ET, Guo Y, Desta Z. 2012. Effects of the CYP2B6*6 allele on catalytic properties and inhibition of CYP2B6 in vitro: implication for the mechanism of reduced efavirenz metabolism and other CYP2B6 substrates in vivo. Drug Metab. Dispos. 40:717-725. http://dx.doi.org/10.1124/dmd.111.042416.
37. Richter T, Murdter TE, Heinkele G, Pleiss J, Tatzel S, Schwab M, Eichelbaum M, Zanger UM. 2004. Potent mechanism-based inhibition of human CYP2B6 by clopidogrel and ticlopidine. J. Pharmacol. Exp. Ther. 308:189. http://dx.doi.org/10.1124/jpet.103.056127.
38. Robertson SM, Maldarelli F, Natarajan V, Formentini E, Alfaro RM, Penzak SR. 2008. Efavirenz induces CYP2B6-mediated hydroxylation of bupropion in healthy subjects. J. Acquir. Immune Defic. Syndr. 49:513-519. http://dx.doi.org/10.1097/QAI.0b013e318183a425.
39. Ngaimisi E, Mugusi S, Minzi OM, Sasi P, Riedel KD, Suda A, Ueda N, Janabi M, Mugusi F, Haefeli WE, Burhenne J, Aklillu E. 2010. Long-term efavirenz autoinduction and its effect on plasma exposure in HIV patients. Clin. Pharmacol. Ther. 88:676-684. http://dx.doi.org/10.1038/clpt.2010.172.
40. Cho DY, Ogburn ET, Jones D, Desta Z. 2011. Contribution of N-glucuronidation to efavirenz elimination in vivo in the basal and rifampin-induced metabolism of efavirenz. Antimicrob. Agents Chemother. 55:1504-1509. http://dx.doi.org/10.1128/AAC.00883-10.